Figure 2
From: Cytokine polymorphisms influence treatment outcomes in SLE patients treated with antimalarial drugs
Combined IL-10/tumor necrosis factor (TNF)α genotype influences TNFα serum levels in SLE patients without antimalarial treatment. After determination of the allele present at positions -1,082 and -308 of the IL-10 and TNFα gene promoters, respectively, patients were classified as genetically high (GG) or low (AA/AG) IL-10 producers and high (AA/AG) or low (GG) TNFα producers. Box plots represent TNFα serum levels in SLE patients not receiving antimalarial therapy classified according to the four possible IL-10/TNFα combined genotypes. Differences were evaluated by the Mann-Whitney U test.